ABSTRACT
Severe Acute Respiratory Syndrome related coronaviruses -2 (SARS CoV-2) infection posed unprecedented challenges to the world. SARS Co-V 2 shows similarity with severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) and are distributed broadly among humans and animals and cause respiratory tract infections. It is imperative for identifying appropriate therapeutic options in response to the SARC CoV-2 outbreak. Here, we discuss the potential drug options for repurposing against Corona Virus Disease 2019 (COVID-19)/SARS-CoV-2. COVID-19 outbreak has emphasized the urgent need for repurposing drugs. We focus here on the existing drugs, based on therapeutic application in influenza and human coronaviruses: SARS and MERS. Hydroxychloroquine (HCQ) has a long-standing history in the prevention and treatment of malaria and has immunomodulatory effects used in various autoimmune disease. Multiple research studies show that HCQ improved virologic clearance, and a combination of HCQ with Azithromycin (AZ) is better in viral clearance. These drugs are relatively safe and may improve the clinical outcome in the patient.